Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Background Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. Th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dirk Schadendorf, Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Paolo Antonio Ascierto, Reinhard Dummer, Michael Manos, Joanna Mangana, Richard D Carvajal, Georgina V Long, Alon Vaisman, Christian Posch, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Carlo Alberto Tondini, Arielle Elkrief, Karijn P M Suijkerbuijk, Mario Mandala, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Matteo S Carlino, Michael Erdmann, Laura Pala, Wilson H Miller Jr, Osama E Rahma, Paul C Lorigan
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/0880e80bb8394806afbc90b0e9140059
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares